Literature DB >> 29086017

Assessing the influence of age and gender on the phenotype of myotonic dystrophy type 2.

Federica Montagnese1, Stefania Mondello2, Stephan Wenninger1, Wolfram Kress3, Benedikt Schoser4.   

Abstract

This study aims to provide a detailed clinical characterization of a large cohort of myotonic dystrophy type 2 (DM2) patients investigating the influence of age and gender as modifying factors of DM2 phenotype. A retrospective study was conducted on 307 patients with genetically confirmed DM2. The following data were analyzed: (1) demographics, (2) clinical features (first symptom, muscular complaints, and multisystemic involvement), (3) diagnostics (serological tests, electromyography, and muscle biopsy). In this cohort (186 females, 121 males), a proximal weakness was the leading symptom at onset (55.4%), followed by myalgia (35.5%) and myotonia (25.4%). Proximal weakness was more common in women than men (64.9 vs. 43.8%, p = 0.0006), whereas being male was associated with higher odds for developing myalgia [OR 2.94 (95% CI 1.53-5.67)]. Patients with muscle weakness at onset were older than those with myalgia and myotonia (p < 0.0001), while each additional disease year was associated with 10% decrease in the odds of developing myotonia [OR 0.9 (95% CI 0.87-0.93)] and 6% decrease of myalgia [OR 0.94 (95% CI 0.91-0.97)]. Cataract and thyroid diseases occurred more frequently in women (p = 0.002 and p = 0.002, respectively). Early onset of DM2 is an independent risk factor for the occurrence of multisystemic involvement [OR 0.94 (95% CI 0.90-0.98)]. In this updated clinical description of DM2 emerges a profound gender and age influence on the phenotype, emphasizing that female gender and ageing may be associated with a higher disease burden. These age- and gender-specific differences should be considered in diagnostics, management, and future clinical studies of DM2.

Entities:  

Keywords:  CNBP; DM2; Myotonic dystrophy type 2; PROMM; Phenotype

Mesh:

Year:  2017        PMID: 29086017     DOI: 10.1007/s00415-017-8653-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  36 in total

1.  Cancer risk among patients with myotonic muscular dystrophy.

Authors:  Shahinaz M Gadalla; Marie Lund; Ruth M Pfeiffer; Sanne Gørtz; Christine M Mueller; Richard T Moxley; Sigurdur Y Kristinsson; Magnus Björkholm; Fatma M Shebl; James E Hilbert; Ola Landgren; Jan Wohlfahrt; Mads Melbye; Mark H Greene
Journal:  JAMA       Date:  2011-12-14       Impact factor: 56.272

2.  Endocrine function over time in patients with myotonic dystrophy type 1.

Authors:  J R Dahlqvist; M C Ørngreen; N Witting; J Vissing
Journal:  Eur J Neurol       Date:  2014-08-25       Impact factor: 6.089

3.  207th ENMC Workshop on chronic respiratory insufficiency in myotonic dystrophies: management and implications for research, 27-29 June 2014, Naarden, The Netherlands.

Authors:  V A Sansone; C Gagnon
Journal:  Neuromuscul Disord       Date:  2015-02-03       Impact factor: 4.296

4.  Proximal myotonic dystrophy--a family with autosomal dominant muscular dystrophy, cataracts, hearing loss and hypogonadism: heterogeneity of proximal myotonic syndromes?

Authors:  B Udd; R Krahe; C Wallgren-Pettersson; B Falck; H Kalimo
Journal:  Neuromuscul Disord       Date:  1997-06       Impact factor: 4.296

5.  [Proximal myotonial myopathy (PROMM): clinical and histology study].

Authors:  G Bassez; S Attarian; P Laforêt; J P Azulay; A Rouche; X Ferrer; J A Urtizberea; J F Pellissier; D Duboc; M Fardeau; J Pouget; B Eymard
Journal:  Rev Neurol (Paris)       Date:  2001-02       Impact factor: 2.607

6.  The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis.

Authors:  Ane Garmendia Madariaga; Silvia Santos Palacios; Francisco Guillén-Grima; Juan C Galofré
Journal:  J Clin Endocrinol Metab       Date:  2014-01-01       Impact factor: 5.958

7.  A family with an unusual myotonic and myopathic phenotype and no CTG expansion (proximal myotonic myopathy syndrome): a challenge for future molecular studies.

Authors:  G Meola; V Sansone; S Radice; S Skradski; L Ptacek
Journal:  Neuromuscul Disord       Date:  1996-05       Impact factor: 4.296

8.  An Age-Standardized Prevalence Estimate and a Sex and Age Distribution of Myotonic Dystrophy Types 1 and 2 in the Rome Province, Italy.

Authors:  Nicola Vanacore; Emanuele Rastelli; Giovanni Antonini; Maria Laura Ester Bianchi; Annalisa Botta; Elisabetta Bucci; Carlo Casali; Sandro Costanzi-Porrini; Manlio Giacanelli; Manuela Gibellini; Anna Modoni; Giuseppe Novelli; Elena Maria Pennisi; Antonio Petrucci; Carlo Piantadosi; Gabriella Silvestri; Chiara Terracciano; Roberto Massa
Journal:  Neuroepidemiology       Date:  2016-02-17       Impact factor: 3.282

9.  Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland.

Authors:  Tiina Suominen; Linda L Bachinski; Satu Auvinen; Peter Hackman; Keith A Baggerly; Corrado Angelini; Leena Peltonen; Ralf Krahe; Bjarne Udd
Journal:  Eur J Hum Genet       Date:  2011-03-02       Impact factor: 4.246

Review 10.  Muscle wasting in myotonic dystrophies: a model of premature aging.

Authors:  Alba Judith Mateos-Aierdi; Maria Goicoechea; Ana Aiastui; Roberto Fernández-Torrón; Mikel Garcia-Puga; Ander Matheu; Adolfo López de Munain
Journal:  Front Aging Neurosci       Date:  2015-07-09       Impact factor: 5.750

View more
  14 in total

1.  Gender difference in clinical conditions among hospitalized adults with myotonic dystrophy.

Authors:  Lijing Ouyang; Yinding Wang; Rodolfo Valdez; Nicholas Johnson; Laurie Gutmann; Natalie Street; Julie Bolen
Journal:  Muscle Nerve       Date:  2019-01-13       Impact factor: 3.217

Review 2.  Repeat-associated RNA structure and aberrant splicing.

Authors:  Melissa A Hale; Nicholas E Johnson; J Andrew Berglund
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2019-07-16       Impact factor: 4.490

3.  Summary of Selected Healthcare Encounters among a Selection of Patients with Myotonic Muscular Dystrophy.

Authors:  Kevin J Bennett; Joshua R Mann; Lijing Ouyang
Journal:  South Med J       Date:  2019-06       Impact factor: 0.954

Review 4.  Sleep Complaints, Sleep and Breathing Disorders in Myotonic Dystrophy Type 2.

Authors:  Andrea Romigi; Michelangelo Maestri; Carmine Nicoletta; Giuseppe Vitrani; Marco Caccamo; Gabriele Siciliano; Enrica Bonanni; Diego Centonze; Alessandro Sanduzzi
Journal:  Curr Neurol Neurosci Rep       Date:  2019-02-09       Impact factor: 5.081

Review 5.  Myotonic Dystrophies: Targeting Therapies for Multisystem Disease.

Authors:  Samantha LoRusso; Benjamin Weiner; W David Arnold
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

6.  Thyroid Hormones Play Role in Sarcopenia and Myopathies.

Authors:  Flavia F Bloise; Thamires S Oliveira; Aline Cordeiro; Tania M Ortiga-Carvalho
Journal:  Front Physiol       Date:  2018-05-23       Impact factor: 4.566

7.  Distribution and Structure of DM2 Repeat Tract Alleles in the German Population.

Authors:  Alexis S Mahyera; Tamara Schneider; Birgit Halliger-Keller; Katja Schrooten; Eva-Maria Hörner; Simone Rost; Wolfram Kress
Journal:  Front Neurol       Date:  2018-06-19       Impact factor: 4.003

8.  Late-onset neuromuscular disorders in the differential diagnosis of sarcopenia.

Authors:  Fabian Hofmeister; Lisa Baber; Uta Ferrari; Stefan Hintze; Stefanie Jarmusch; Sabine Krause; Peter Meinke; Stefan Mehaffey; Carl Neuerburg; Fabiana Tangenelli; Benedikt Schoser; Michael Drey
Journal:  BMC Neurol       Date:  2021-06-25       Impact factor: 2.474

Review 9.  Core Clinical Phenotypes in Myotonic Dystrophies.

Authors:  Stephan Wenninger; Federica Montagnese; Benedikt Schoser
Journal:  Front Neurol       Date:  2018-05-02       Impact factor: 4.003

10.  Myotonic Dystrophy-A Progeroid Disease?

Authors:  Peter Meinke; Stefan Hintze; Sarah Limmer; Benedikt Schoser
Journal:  Front Neurol       Date:  2018-07-25       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.